PHIND Seminar - Patricia A. Deverka, MD, MS, MBE & Kathryn A. Phillips, PhD @ Zoom - See Description for Zoom Link
May 18, 2021 @ 11:00 am – 12:00 pm
2021-05-18T11:00:00-07:00
2021-05-18T12:00:00-07:00
Zoom - See Description for Zoom Link
Cost:
Free
Contact:
Ashley Williams

PHIND Seminar Series: Multi-Cancer Early Detection Screening Tests – “Liquid Biopsy Tests” – Are Here – But Will Payers Provide Insurance Coverage?

 

Patricia A. Deverka, MD, MS, MBE
Executive Director
Deverka Consulting, LLC

 

Kathryn A. Phillips, PhD
Professor of Health Economics and Health Services Research
Founding Director, UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)

 

Location: Zoom
Webinar URL: https://stanford.zoom.us/s/99194110894
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Webinar ID: 991 9411 0894
Passcode: 044958

11:00am – 12:00pm Seminar & Discussion
RSVP Here

 

ABSTRACT
The emergence of Multi-Cancer Early Detection Screening Tests (MCED) – “liquid biopsy screening tests” – has generated enormous interest because they could fundamentally shift how cancer screening is done. One company is already offering an MCED test for clinical use as a “lab developed test” (LDT) – and thus addressing the question of “who will pay” has become urgent. These tests offer potentially transformative screening and clinical benefits, but their characteristics present unique challenges to payer coverage decision-making and generate concerns about the potentially high cost of widespread adoption.

We will present our ongoing work on examining the unique challenges that MCED present for payer coverage decision-making, drawing on our extensive experience with coverage and reimbursement for new technologies. We will focus on identifying the evidence generation strategies that could be pursued now to inform payer decision-making so that coverage policies can be developed that are appropriate and equitable for this ground-breaking technology.

 

ABOUT PATRICIA A. DEVERKA
Dr. Deverka is the Executive Director at Deverka Consulting, LLC where she focuses on helping biotechnology companies and start-ups develop evidence to support payer coverage and clinical adoption of innovative technologies.  Her most recent projects have focused on breakthrough tests and drugs focused on population genomic screening, cancer, and ultra-rare disorders.  Prior to starting her consulting practice, Dr. Deverka has worked in the fields of health economics and outcomes research in both non-profit and for-profit settings as a researcher, educator, and department head. She has extensive experience with patient-centered outcomes research, drug and diagnostic reimbursement planning, cost- effectiveness analysis, and bioethical issues surrounding the use of new technologies. While working in academia and several non-profit firms, she has participated in numerous NIH-funded studies to evaluate policy barriers to clinical integration of new genomic technologies and has published extensively on strategies to promote evidence generation and data sharing. She is a member of the National Human Genome Research Institute (NHGRI)’s Genomic Medicine Work Group and serves as a member of NHGRI’s Advisory Council. Deverka has a medical degree from the University of Pittsburgh and is board certified in General Preventive Medicine and Public Health.  She also has a master’s degree in bioethics from the University of Pennsylvania and completed a policy fellowship at Duke University’s Institute for Genome Sciences and Policy.

 

ABOUT KATHRYN A. PHILLIPS
Kathryn A. Phillips founded and leads the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), which focuses on developing objective evidence on how to effectively, efficiently, and equitably implement precision/personalized medicine into health care. Kathryn has published over 150 peer-reviewed articles in major journals including JAMA, New England Journal of Medicine, Science, and Health Affairs. She has had continuous funding from NIH as a PI for over 25 years and was recently awarded a 5-year NIH grant to examine payer coverage and economic value for emerging genomic technologies (cell-free DNA tests and tests based on polygenic risk scores). Kathryn serves on the editorial boards for Health Affairs, Value in Health, JAMA Internal Medicine, Genetics in Medicine; is a member of the National Academy of Medicine Roundtable on Genomics and Precision Health; and has served on the governing Board of Directors for GenomeCanada and as an advisor to the FDA, CDC, and the President’s Council of Advisors on Science and Technology. She has also served as an advisor to many diagnostics, sequencing, and pharmaceutical companies. Kathryn is Chair of the Global Economics and Evaluation of Clinical Sequencing Working Group, and a member of an evidence review committee for the Institute for Clinical and Economic Review (ICER). 

 

 

Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology